European Payers Target Marketing Exclusivity For Orphan Regulation Reform
European payers are calling for changes to the EU’s orphan drug rules that would transform the incentives system and avoid the market distortions enabled by the current legislation.
You may also be interested in...
European Commission plans for an overhaul of the pharmaceutical legislation would halve market protection for orphan drugs and risk the predictability of the regulatory system, warns industry expert.
Overhaul of the pharmaceutical legislation in the EU is an opportunity to learn from COVID-19, says European industry body.
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.